Drug Approval | May 14, 2026
Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
NEJM study shows strong protection across strains
Hair care & quick commerce shine
These check-ups will be conducted through ESIC’s extensive network of hospitals, with a focus on early diagnosis, preventive healthcare, and continuous health monitoring
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The 40-second film brings children to the forefront of the narrative
The approval enables the company to directly sell health insurance plans to individuals and families while integrating its managed healthcare delivery model into retail offerings
Subscribe To Our Newsletter & Stay Updated
